




Investor Fact Sheet

Based on semiannual report 2020/21


(Unaudited Swiss GAAP FER figures)
in thousand CHF

	Half-year 2020/21	in %	Half-year 2019/20	in %	Change	in %
Sales of goods and services group	199 333	100.0 %	190 622	100.0 %	8 711	4.6 %
Ypsomed Diabetes Care	83 918	42.1 %	92 105	48.3 %	-8 187	-8.9 %
Ypsomed Delivery Systems	108 328	54.3 %	91 115	47.8 %	17 213	18.9 %
Others	7 087	3.6 %	7 402	3.9 %	-315	-4.3 %
Operating profit	8 342	4.2 %	9 035	4.7 %	-693	-7.7 %
Financial income	3 608	1.8 %	3 789	2.0 %	-181	-4.8 %
Financial expenses	-4 320	-2.2 %	-3 805	-2.0 %	-515	13.5 %
Income taxes	-1 102	-0.6 %	-1 416	-0.7 %	314	-22.2 %
Net profit	6 528	3.3 %	7 603	4.0 %	-1 075	-14.1 %
Earnings per share in CHF	0.52		0.60		-0.09	-14.1 %
Operating profit	8 342	4.2 %	9 035	4.7 %	-693	-7.7 %
Depreciation and impairment of fixed assets	15 698		13 413		2 285	17.0 %
Amortisation and impairment of intangible assets	9 793		9 301		493	5.3 %
EBITDA (Operating profit before depreciation and amortisation)	33 834	17.0 %	31 749	16.7 %	2 084	6.6 %
Equity ratio in %	53.4 %		55.6 %		-2.2 %	
Investments in fixed assets	32 085		40 846		-8 760	-21.4 %
Investments in intangible assets	28 586		13 324		15 261	114.5 %
Number of employees	1 816		1 674		142	8.5 %
Number of full-time positions	1 727		1 600		127	8.0 %

Development of turnover at group level



Development of EBIT at group level



* In the half-year 2018/19, only contributions from continuing operations. For information about the discontinued operations, see Annual Report 2019/20, note 21, page 59.



Ypsomed Diabetes Care

With its mylife™ Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed's subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).

Diabetes: A global disease with pandemic growth predicted in the coming 20 years. Currently diabetes is growing at approximately 9% p. a. Due to that fact Ypsomed is expanding its network of subsidiaries consequently with its outstanding product portfolio.

mylife™ product portfolio (selection)



Ypsomed Delivery Systems

Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world's largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.

Trends for future drugs: Drugs are becoming more specific, e.g. in the treatment of autoimmune diseases. Instead of a generic drug (e.g. Humira®), a large number of new, very specific drugs come onto the market. New drugs for Alzheimer's disease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneous injection open up opportunities for self-medication with auto- and patch injectors.

YDS product portfolio (selection)



Legal disclaimer: The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG, its advisors or representatives, nor their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as "may", "plans", "expects", "believes" and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.